SAN DIEGO (BUSINESS WIRE) $ARCT #ClinicalTrial Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare dise.
Stock Market | FinancialContent Business Page financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.
Analysts expect Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Get Rating) to report sales of $3.33 million for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Arcturus Therapeutics’ earnings, with the highest sales estimate coming in at $6.29 million and the lowest estimate coming in at $1.32 million. Arcturus Therapeutics reported […]
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Equities research analysts expect Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Get Rating) to post $3.33 million in sales for the current quarter, Zacks reports. Four analysts have issued estimates for Arcturus Therapeutics’ earnings, with the lowest sales estimate coming in at $1.32 million and the highest estimate coming in at $6.29 million. Arcturus Therapeutics reported […]